eIF2A in translational control
翻译控制中的 eIF2A
基本信息
- 批准号:9883230
- 负责人:
- 金额:$ 30.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-01-15 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:3T3-L1 CellsAdipocytesAffectAge-MonthsAntigen PresentationApoptosisBindingBiochemicalCell Cycle ProgressionCell LineCell modelCellsCharacteristicsCodon NucleotidesComplexCryoelectron MicroscopyDevelopmentDiabetes MellitusDiseaseDrug TargetingEscherichia coliEtiologyEukaryotaEukaryotic Initiation FactorsEventFatty LiverGene ExpressionGene Expression RegulationGenesGenetic TranscriptionGoalsGuanosine TriphosphateHigh Fat DietHomeostasisHomologous GeneIn VitroKnock-outKnockout MiceLinkLipidsLymphomaMajor Histocompatibility ComplexMalignant NeoplasmsMammalsMediatingMessenger RNAMetabolicMetabolic DiseasesMetabolic syndromeMinorModelingMolecularMouse StrainsMusObesityOutcomePathway interactionsPeptide Initiation FactorsPhenotypePhosphorylationPhosphotransferasesPhysiologicalPlayPredispositionProcessProductionPropertyProtein BiosynthesisProteinsReactionRecombinant ProteinsRecombinantsRegulationReportingResistanceRibosomesRoleSerumStimulusStressStructureSystemTP53 geneTestingTimeTissuesTransfer RNATranslationsValidationViral Proteinsbiological adaptation to stresscell growthglucose tolerancehuman diseasein vivoinnovationinterestknockout animalmouse modelpolypeptidepreferencereconstitutionrecruitresponseribosome profilingtranscriptometranscriptome sequencingtranslation assaytranslatometumortumor initiationtumor progression
项目摘要
Initiation of protein synthesis in eukaryotes is a complex process requiring more than 12 different initiation
factors, comprising over 30 polypeptide chains. The functions of many of these factors have been established
in great detail; however, the precise role of some of them and their mechanism of action still remain not well
understood. eIF2A is a single chain 65 kDa protein that was initially believed to serve as the functional
homologue of prokaryotic IF2, since eIF2A and IF2 catalyze biochemically similar reactions, i.e. they stimulate
initiator methionyl-tRNA (Met-tRNAMeti) binding to the small ribosomal subunit. However, subsequent
identification of a heterotrimeric 126 kDa factor, eIF2() showed that this factor and not eIF2A is primarily
responsible for the binding of Met-tRNAMeti to 40S ribosomal subunits in eukaryotes. In mammals, four stress-
activated kinases reduce the level of active eIF2 by phosphorylating the eIF2subunit and, consequently,
reducing the global level of translation. However, translation of many cellular and viral proteins appeared to be
resistant to eIF2α phosphorylation despite requiring Met-tRNAMeti. It was found that a subset of factors,
including eIF2A, can promote efficient recruitment of Met-tRNAMeti to 40S/mRNA complexes under conditions
of inhibition of eIF2 activity, or its absence. Recently, eIF2A was also reported to be involved in non-AUG
dependent initiation in higher eukaryotes and the control of antigen presentation by major histocompatibility
complex (MHC) class I molecules, the integrated stress response and tumor initiation and progression. All of
these events were affected by eIF2A silencing in cellular models. Yet, the precise role of eIF2A in vivo, as well
as the precise mechanism of its action still remain largely enigmatic. There is a fundamental gap in our
understanding of how eIF2A functions in mammalian systems in vivo and ex vivo. To fill in this gap above and
to continue the physical and functional characterization of a eukaryotic/mammalian eIF2A, we have created a
viable homozygous eIF2A-total knockout mouse strain and obtained recombinant eIF2A expressed in E. coli
cells. The ultimate goal of this proposal is to understand the function of eIF2A in vivo and in vitro. This goal will
be achieved by a combination of in vitro, ex vivo and in vivo (mouse model) approaches. The outcome of this
proposal will be important for understanding the basic mechanisms of the translational control of gene
expression in higher eukaryotes, especially as part of the stress response.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anton A. Komar其他文献
[Frequency of using codons in mRNA and coding of the domain structure of proteins].
[mRNA中密码子的使用频率和蛋白质结构域的编码]。
- DOI:
- 发表时间:
1989 - 期刊:
- 影响因子:0
- 作者:
Igor A. Krasheninnikov;Anton A. Komar;Adzhubeĭ Ia - 通讯作者:
Adzhubeĭ Ia
Anton A. Komar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anton A. Komar', 18)}}的其他基金
Safer and more effective FIX therapeutics: impact of codon optimization
更安全、更有效的 FIX 疗法:密码子优化的影响
- 批准号:
10372111 - 财政年份:2020
- 资助金额:
$ 30.16万 - 项目类别:
Safer and more effective FIX therapeutics: impact of codon optimization
更安全、更有效的 FIX 疗法:密码子优化的影响
- 批准号:
10600842 - 财政年份:2020
- 资助金额:
$ 30.16万 - 项目类别:
Understanding the impact of disease causing mutations in FIX
了解引起 FIX 突变的疾病的影响
- 批准号:
8752096 - 财政年份:2014
- 资助金额:
$ 30.16万 - 项目类别:
相似国自然基金
CCL5/CCR5通路调控猪皮下脂肪细胞向肌肉迁移及其对肌内脂肪影响的机制研究
- 批准号:32372853
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于胞葬作用探讨THBS1/FUNDC2/RAB7蛋白复合体影响鼻咽癌巨噬细胞脂肪酸氧化及存活的机制
- 批准号:82303335
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
微小微单胞菌调控巨噬细胞脂肪酸代谢酶m6A修饰影响结直肠癌免疫治疗的机制研究
- 批准号:82372732
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
m6A甲基化双向调控Rab7/Bcl2l1介导自噬影响糖尿病性骨质疏松症脂肪干细胞骨向分化的机制研究
- 批准号:82370938
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
长链非编码RNA H19X通过调控FADS2影响脂肪干细胞衰老与功能的机制研究
- 批准号:82302814
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of Adrb3 Antagonists for the Treatment of Pain
用于治疗疼痛的 Adrb3 拮抗剂的开发
- 批准号:
10730831 - 财政年份:2023
- 资助金额:
$ 30.16万 - 项目类别:
Trimming the fat with small proteins: Micropeptides in adipogenesis
用小蛋白质减少脂肪:脂肪生成中的微肽
- 批准号:
10655394 - 财政年份:2022
- 资助金额:
$ 30.16万 - 项目类别:
Assay development for characterization of Adrb3 antagonists as pain therapeutics
Adrb3 拮抗剂作为疼痛治疗药物表征的测定方法开发
- 批准号:
10287083 - 财政年份:2021
- 资助金额:
$ 30.16万 - 项目类别:
Mechanisms of Environmental-Mixture Induced Metabolic Disruption
环境混合物引起的代谢紊乱的机制
- 批准号:
10225688 - 财政年份:2020
- 资助金额:
$ 30.16万 - 项目类别: